ArticleInterdisciplinary cardiovascular and thoracic surgery2026
Salvage Surgery Following Definitive Chemoradiotherapy and Immune Checkpoint Inhibitor Therapy for Locally Advanced Thymic Carcinoma.
Article in Interdisciplinary cardiovascular and thoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surgical resection improves prognosis for thymic carcinoma. Recent phase II trials have indicated the efficacy of immune checkpoint inhibitor therapy in unresectable disease. Here, we report a case of salvage surgery following immune checkpoint inhibitor therapy for an initially unresectable, locally advanced thymic carcinoma in a 67-year-old woman. Computed tomography revealed an anterior mediastinal mass and enlarged anterior mediastinal lymph nodes, diagnosed as an unresectable thymic epithelial tumour, due to suspected invasion into the left main pulmonary artery. Thoracoscopic biopsy confirmed the diagnosis of squamous cell carcinoma with high programmed cell death-ligand 1 expression (90%-100%). Following definitive chemoradiotherapy, the patient received durvalumab, which reduced the primary tumour size and resolved lymphadenopathy, without immune-related adverse events. Salvage surgery was performed without invasion of the great vessels. The patient remained disease-free at 2 years postoperatively. Salvage surgery following immune checkpoint inhibitor therapy may be a viable treatment option for thymic carcinoma with high programmed cell death-ligand 1 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.